Form 4: Blueprint Medicines Director Jeffrey Albers Reports Significant RSU Grant

Blueprint Medicines Corporation Director Jeffrey W. Albers reported the acquisition of 3,902 shares of common stock through a restricted stock unit grant, increasing his beneficial ownership to 150,532 shares.

Summary

• Jeffrey W. Albers, a Director of Blueprint Medicines Corp. (BPMC), reported a transaction on June 18, 2025.
• The transaction involved the acquisition of 3,902 shares of common stock.
• These shares were acquired through a grant of restricted stock units (RSUs) at a price of $128.12 per share.
• Following this transaction, Mr. Albers' total beneficial ownership in Blueprint Medicines Corp. increased to 150,532 shares.
• The restricted stock units are set to vest 100% on the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive signal of continued alignment between management and shareholder interests, though it is a routine compensation event rather than a strategic investment.

Positives

• Director Jeffrey W. Albers increased his beneficial ownership in Blueprint Medicines Corp. by 3,902 shares, signaling continued confidence in the company.
• The grant of restricted stock units aligns the director's long-term interests with those of shareholders through a future vesting schedule.

Future Outlook

The restricted stock units granted to Director Albers are set to vest 100% on the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders, indicating a future commitment and alignment with long-term company performance.

Industry Context

This Form 4 filing reflects a routine insider transaction related to director compensation, common across publicly traded companies. Such grants are a standard mechanism for aligning the interests of corporate directors with long-term shareholder value, particularly in the biotechnology and pharmaceutical sectors where long-term development cycles are prevalent.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with long-term shareholder value due to the RSU grant and vesting schedule.

Next Steps

• Vesting of the 3,902 restricted stock units on the earlier of June 18, 2026, or the next annual meeting of Blueprint Medicines Corporation's stockholders.

Key Dates

Keywords

Blueprint Medicines, BPMC, SEC Form 4, insider transaction, restricted stock units, RSU grant, director compensation, beneficial ownership, stock acquisition